Armata Pharmaceuticals Inc.
10/03/2024 | Press release | Distributed by Public on 10/03/2024 14:16
Management Change/Compensation Form 8 K
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e)
On September 26, 2024, Armata Pharmaceuticals, Inc. (the "Company") disclosed that it had reached an agreement with Richard Rychlik, the Company's Vice President, Corporate Controller, pursuant to which Mr. Rychlik's employment would conclude effective as of September 30, 2024.
In connection with Mr. Rychlik's separation, on September 30, 2024, the Company entered into a Confidential Separation and Release Agreement with Mr. Rychlik (the "Separation Agreement") pursuant to which, in consideration for Mr. Rychlik's general release of claims in favor of the Company and its affiliates, Mr. Rychlik will be entitled to the continued payment of his base salary through December 31, 2024 and subsidized COBRA premiums for the same period. Mr. Rychlik's receipt of the foregoing payments and benefits is subject to his compliance with the Separation Agreement.
The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein.